RATIONALE: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) genes. Sinoatrial node dysfunction associated with CPVT may increase the risk for ventricular arrhythmia (VA). OBJECTIVE: To test the hypothesis that CPVT is suppressed by supraventricular overdrive stimulation. METHODS AND RESULTS: Using CPVT mouse models (Casq2(-/-) and RyR2(R4496C/+) mice), the effect of increasing sinus heart rate was tested by pretreatment with atropine and by atrial overdrive pacing. Increasing intrinsic sinus rate with atropine before catecholamine challenge suppressed ventricular tachycardia in 86% of Casq2(-/-) mice (6/7) and significantly reduced the VA score (atropine: 0.6±0.2 versus vehicle: 1.7±0.3; P<0.05). Atrial overdrive pacing completely prevented VA in 16 of 19 (84%) Casq2(-/-) and in 7 of 8 (88%) RyR2(R4496C/+) mice and significantly reduced ventricular premature beats in both CPVT models (P<0.05). Rapid pacing also prevented spontaneous calcium waves and triggered beats in isolated CPVT myocytes. In humans, heart rate dependence of CPVT was evaluated by screening a CPVT patient registry for antiarrhythmic drug-naïve individuals that reached >85% of their maximum-predicted heart rate during exercise testing. All 18 CPVT patients who fulfilled the inclusion criteria exhibited VA before reaching 87% of maximum heart rate. In 6 CPVT patients (33%), VA were paradoxically suppressed as sinus heart rates increased further with continued exercise. CONCLUSIONS: Accelerated supraventricular rates suppress VAs in 2 CPVT mouse models and in a subset of CPVT patients. Hypothetically, atrial overdrive pacing may be a therapy for preventing exercise-induced ventricular tachycardia in treatment-refractory CPVT patients.
RATIONALE: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) genes. Sinoatrial node dysfunction associated with CPVT may increase the risk for ventricular arrhythmia (VA). OBJECTIVE: To test the hypothesis that CPVT is suppressed by supraventricular overdrive stimulation. METHODS AND RESULTS: Using CPVT mouse models (Casq2(-/-) and RyR2(R4496C/+) mice), the effect of increasing sinus heart rate was tested by pretreatment with atropine and by atrial overdrive pacing. Increasing intrinsic sinus rate with atropine before catecholamine challenge suppressed ventricular tachycardia in 86% of Casq2(-/-) mice (6/7) and significantly reduced the VA score (atropine: 0.6±0.2 versus vehicle: 1.7±0.3; P<0.05). Atrial overdrive pacing completely prevented VA in 16 of 19 (84%) Casq2(-/-) and in 7 of 8 (88%) RyR2(R4496C/+) mice and significantly reduced ventricular premature beats in both CPVT models (P<0.05). Rapid pacing also prevented spontaneous calcium waves and triggered beats in isolated CPVT myocytes. In humans, heart rate dependence of CPVT was evaluated by screening a CPVT patient registry for antiarrhythmic drug-naïve individuals that reached >85% of their maximum-predicted heart rate during exercise testing. All 18 CPVT patients who fulfilled the inclusion criteria exhibited VA before reaching 87% of maximum heart rate. In 6 CPVT patients (33%), VA were paradoxically suppressed as sinus heart rates increased further with continued exercise. CONCLUSIONS: Accelerated supraventricular rates suppress VAs in 2 CPVT mouse models and in a subset of CPVT patients. Hypothetically, atrial overdrive pacing may be a therapy for preventing exercise-induced ventricular tachycardia in treatment-refractory CPVT patients.
Authors: H Swan; K Piippo; M Viitasalo; P Heikkilä; T Paavonen; K Kainulainen; J Kere; P Keto; K Kontula; L Toivonen Journal: J Am Coll Cardiol Date: 1999-12 Impact factor: 24.094
Authors: Alex V Postma; Isabelle Denjoy; Theo M Hoorntje; Jean-Marc Lupoglazoff; Antoine Da Costa; Pascale Sebillon; Marcel M A M Mannens; Arthur A M Wilde; Pascale Guicheney Journal: Circ Res Date: 2002-10-18 Impact factor: 17.367
Authors: Christian van der Werf; Ineke Nederend; Nynke Hofman; Nan van Geloven; Corné Ebink; Ingrid M E Frohn-Mulder; A Marco W Alings; Hans A Bosker; Frank A Bracke; Freek van den Heuvel; Reinier A Waalewijn; Hennie Bikker; J Peter van Tintelen; Zahurul A Bhuiyan; Maarten P van den Berg; Arthur A M Wilde Journal: Circ Arrhythm Electrophysiol Date: 2012-07-10
Authors: Silvia G Priori; Carlo Napolitano; Mirella Memmi; Barbara Colombi; Fabrizio Drago; Maurizio Gasparini; Luciano DeSimone; Fernando Coltorti; Raffaella Bloise; Roberto Keegan; Fernando E S Cruz Filho; Gabriele Vignati; Abraham Benatar; Angelica DeLogu Journal: Circulation Date: 2002-07-02 Impact factor: 29.690
Authors: Sonia Franciosi; Thomas M Roston; Frances K G Perry; Bjorn C Knollmann; Prince J Kannankeril; Shubhayan Sanatani Journal: J Cardiovasc Electrophysiol Date: 2019-07-11
Authors: Hengtao Zhang; Albert Y Sun; Jong J Kim; Victoria Graham; Elizabeth A Finch; Igor Nepliouev; Guiling Zhao; Tianyu Li; W J Lederer; Jonathan A Stiber; Geoffrey S Pitt; Nenad Bursac; Paul B Rosenberg Journal: Proc Natl Acad Sci U S A Date: 2015-09-30 Impact factor: 11.205
Authors: Alexey V Glukhov; Anuradha Kalyanasundaram; Qing Lou; Lori T Hage; Brian J Hansen; Andriy E Belevych; Peter J Mohler; Björn C Knollmann; Muthu Periasamy; Sandor Györke; Vadim V Fedorov Journal: Eur Heart J Date: 2013-11-11 Impact factor: 29.983
Authors: Thomas A Csepe; Jichao Zhao; Brian J Hansen; Ning Li; Lidiya V Sul; Praise Lim; Yufeng Wang; Orlando P Simonetti; Ahmet Kilic; Peter J Mohler; Paul M L Janssen; Vadim V Fedorov Journal: Prog Biophys Mol Biol Date: 2015-12-30 Impact factor: 3.667
Authors: Daniel J Flores; ThuyVy Duong; Luke O Brandenberger; Apratim Mitra; Aditya Shirali; John C Johnson; Danielle Springer; Audrey Noguchi; Zu-Xi Yu; Steven N Ebert; Andreas Ludwig; Bjorn C Knollmann; Mark D Levin; Karl Pfeifer Journal: Hum Mol Genet Date: 2018-05-01 Impact factor: 6.150